https://www.selleckchem.com/pr....oducts/8-oh-dpat-8-h
The prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease are increasing globally. Body weight loss reduces the risk of morbidity and mortality in obese individuals and thus, pharmacotherapies that induce weight loss can be of great value in improving the health and well-being of people living with obesity. Treatment with amylin and calcitonin receptor agonists reduce food intake and induce weight loss in several animal models, and a number of companies have started clinic
Like
Comment
Share
